Different induction therapy protocols experience based on depleting antibodies for kidney transplantation

Aim. To analyze the efficacy and safety of different induction therapy protocols experience based on depleting antibodies for kidney transplantation (ATGAM, Timoglobulin).

Material and methods. The study included 107 non-sensitized patients who underwent primary kidney allotransplantation in the period from January 2012 to March 2014. Patients were divided into 3 groups according to the ongoing induction immunosuppressive therapy. Group I, patients receiving the drug ATGAM (n = 67). Group II – Timoglobulin (n = 30). Group III, patients received a combination of the introduction of basiliximab and ATGAM (n = 10). All patients received basic triple immunosuppressive therapy: tacrolimus, mycophenolic acid, methylprednisolone tapering.

Results. The incidence of acute rejection in group I – 7,5% , in group II – 0%, in group III – 0% (p = 0,15). The incidence of severe thrombocytopenia in group I – 2,7%, in group II – 0% (p < 0,05), in group III – 10%. Incidence of CMV viremia in group I – 6,16%, in group II – 6,6%, in the group III – 10%, respectively (p > 0,05). In the 2-nd and 3-rd group registered one case of CMV pneumonia in the early postoperative period.

Conclusion. Use of exhaustible polyclonal antibodies as drugs of choice for renal transplantation induction therapy in primary unsensitized patients is warranted. Further research is needed for evaluation of 5- and 10-year results.

1. Арзуманов, С.В. Трансплантология. Фармакотерапия без ошибок / С.В. Арзуманов, В.М. Захаревич, И.Г. Ким; Под ред. С.В. Готье, Я.Г. Мойсюк. – М.: E-noto, 2014. – С. 81–106, 131–146. Arzumanov S.V., Zakharevich V.M., Kim I.G.; Gautier S.V., Moysyuk Ya.G., eds. Transplantologiya. Farmakoterapiya bez oshibok [Transplantation. Pharmacotherapy without errors]. Moscow: E-noto Publ., 2014. 81–106, 131–146. (In Russian).

2. Очерки клинической трансплантологии / Под ред. С.В. Готье. – М. – Тверь:Триада, 2009. – С. 88–93. Gautier S.V., ed. Ocherki klinicheskoy transplantologii [Essays clinical transplantation]. Moscow–Tver': Triada Publ., 2009. 88–93. (In Russian).

3. Колбин, А.С. Клинико-экономический анализ тимоглобулина для профилактики и лечения отторжения трансплантата при пересадке почки / А.С. Колбин, А.А. Курылёв, А.В. Прасолов // Качественная клиническая практика. – 2013. – № 1. – С. 15–26. Kolbin A.S., Kurylev A.A., Prasolov A.V. Kliniko-ekonomicheskiy analiz Timoglobullina dlya profilaktiki i lecheniya ottorzheniya transplantata pri peresadke pochki [Clinical and economic analysis Timoglobullina for the prevention and treatment of transplant rejection in the kidney transplant]. Kachestvennaya klinicheskaya praktika. 2013; 1: 15–26. (In Russian).

4. KDIGO clinical practice guideline for the care of kidney transplant recipients / Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group // Am. J. Transplant. – 2009. – Vol. 9, Suppl. 3. – S1–S155.

5. Scientific Registry of Transplant Recipients (SRTR) [Electronic resource]. –Режим доступа: http://www.srtr.org. – Загол. с экрана. (Дата

6. обращения 30 марта 2014 г.).

7. Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень жизненно необходимых и важнейших лекарственных препаратов [Электронный ресурс]. – Режим доступа: http://grls.rosminzdrav.ru/pricelims.aspx. – Загол. с экрана (по состоянию на 30.03.2014). Gosudarstvennyy reestr predel'nykh otpusknykh tsen proizvoditeley na lekarstvennye preparaty, vklyuchennye v perechen' zhiznenno neobkhodimykh I vazhneyshikh lekarstvennykh preparatov [State register limit ex-works prices of medicines included in the list of vital and essential medicines]. Available at:

8. http://grls.rosminzdrav.ru/pricelims. aspx. (Accessed 30 March 2014). (In Russian).

9. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Thymoglobulin Antibody Immunosuppression in Living Donor Recipients Investigators / A.O. Gaber, A.J. Matas, M.L. Henry [et al.] // Transplantation. – 2012. – Vol. 94, N.4. – P. 331–337.

10. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and antithymocyte globulin / A.B. Libório, T.R. Mendoza, R.M. Esmeraldo [et al.] // Int. Immunopharmacol. – 2011. – Vol. 11,

11. N.11. – P. 1832–1836.

12. A prospective, randomized, doubleblinded comparison of thymoglobulin versus Atgam forinduction immunosuppressive therapy: 10-year results / K.L. Hardinger, S. Rhee, P. Buchanan [et al.] // Transplantation. – 2008. – Vol. 86, N.7. – P. 947–952.

13. Induction with basiliximab plus thymoglobulin is effective and safe in oldfor-old renal transplantation: six-month results of a prospective clinical study / E. Favi, A. Gargiulo, G. Spagnoletti [et al.] // Transplant. Proc. – 2010. – Vol. 42, N.4. – P. 1114–1117.

14. Thiyagarajan, U.M. Thymoglobulin and its use in renal transplantation: a review / U.M. Thiyagarajan, A. Ponnuswamy, A. Bagul // Am. J. Nephrol. – 2013. – Vol. 3, N.6. – P. 586–601.